GSK, ovarian cancer
Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of ...
In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
GSK said. Zejula is an oral, once-daily poly-ADP ribose polymerase inhibitor currently being evaluated in multiple pivotal trials. Jemperli, is a monoclonal antibody used as an anti-cancer ...
GSK (GSK) announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended expanding ...
In another press release, GSK announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent ...
A diet low in omega-6 and enriched with omega-3 fatty acids and fish oil for prostate cancer patients on active surveillance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback